{"id":16025,"date":"2021-05-27T19:19:25","date_gmt":"2021-05-27T19:19:25","guid":{"rendered":"https:\/\/www.canaaf.org\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/"},"modified":"2022-08-04T15:11:22","modified_gmt":"2022-08-04T15:11:22","slug":"concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543","status":"publish","type":"post","link":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/","title":{"rendered":"Concert Pharmaceuticals d\u00e9bute l&rsquo;essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543)"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1331.2px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_6 1_6 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:16.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:11.52%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:11.52%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>La FCANAA est ravie d&rsquo;annoncer le lancement de THRIVE-AA2, le deuxi\u00e8me essai clinique pr\u00e9vu de phase 3 qui vise \u00e0 \u00e9valuer l&rsquo;efficacit\u00e9 et l&rsquo;innocuit\u00e9 du CTP-543, un inhibiteur oral des Janus kinases (JAK), chez les patientes et patients adultes atteints d\u2019alop\u00e9cie areata mod\u00e9r\u00e9e \u00e0 grave. Concert pr\u00e9voit communiquer les r\u00e9sultats pr\u00e9liminaires de THRIVE-AA2 vers la fin de 2022. De plus, Concert estime que les r\u00e9sultats positifs des essais de phase 3 THRIVE-AA1 et THRIVE-AA2 pourraient servir de fondation \u00e0 la soumission d&rsquo;une demande de nouveau m\u00e9dicament \u00e0 la Food and Drug Administration (FDA) am\u00e9ricaine au d\u00e9but de 2023 pour le CTP-543, pour le traitement de l\u2019alop\u00e9cie areata mod\u00e9r\u00e9e \u00e0 grave chez les patientes et patients adultes. Il s\u2019agit d\u2019une nouvelle tr\u00e8s excitante, car il n\u2019existe actuellement aucune option th\u00e9rapeutique approuv\u00e9e par la FDA ou par Sant\u00e9 Canada pour le traitement de l\u2019alop\u00e9cie areata chez les adultes ou les jeunes.<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>Qu\u2019est-ce que l&rsquo;essai THRIVE-AA2?<\/strong><\/span><\/p>\n<p>Le THRIVE-AA2 est un essai clinique randomis\u00e9, \u00e0 double insu, contr\u00f4l\u00e9 par placebo, men\u00e9 aux \u00c9tats-Unis, au Canada et en Europe, pour les patientes et patients adultes atteints d\u2019alop\u00e9cie areata mod\u00e9r\u00e9e \u00e0 grave. Cet essai \u00e9value la repousse des cheveux apr\u00e8s 24 semaines de prise du CTP-543 ou d\u2019un placebo. La croissance des cheveux est \u00e9valu\u00e9e \u00e0 l\u2019aide de l\u2019outil de gravit\u00e9 de l\u2019alop\u00e9cia (Severity of Alopecia Tool, SALT). Comme vous vous en souvenez peut-\u00eatre, lors de notre <a href=\"https:\/\/drive.google.com\/file\/d\/1u8PsUl6ZsHfv5V6vJmD3zJqW6OKowjmD\/view\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #e31836;\">pr\u00e9sentation sur les essais cliniques<\/span><\/a> en f\u00e9vrier dernier (2021), un essai clinique randomis\u00e9 \u00e0 double insu est un essai o\u00f9 ni les chercheuses et chercheurs ni les patientes et patients ne savent quel traitement est administr\u00e9 (entre le CTP 543 ou un placebo). Cette ignorance a pour but d\u2019\u00e9viter tout biais dans la s\u00e9lection des patientes et patients et l\u2019analyse des r\u00e9sultats. La FDA a accord\u00e9 au CTP-543 la d\u00e9signation de th\u00e9rapie r\u00e9volutionnaire [Breakthrough Therapy] pour le traitement des patientes et patients adultes atteints d\u2019alop\u00e9cie areata mod\u00e9r\u00e9e \u00e0 grave et la d\u00e9signation de proc\u00e9dure acc\u00e9l\u00e9r\u00e9e [Fast Track] pour le traitement de l\u2019alop\u00e9cie areata.<\/p>\n<p><span style=\"text-decoration: underline;\"><strong>En apprendre plus sur le CTP-543<\/strong><\/span><\/p>\n<p>Le CTP-543 est un inhibiteur s\u00e9lectif oral des Janus kinases, JAK1 et JAK2, plus connu sous le nom d&rsquo;inhibiteur de JAK. Les cellules de notre syst\u00e8me immunitaire communiquent entre elles \u00e0 l\u2019aide de messagers chimiques appel\u00e9s cytokines. Parmi les nombreuses cytokines produites par notre organisme, on trouve les Janus kinases (JAK) et le signal transducteur et activateur de la transcription (STAT). Les prot\u00e9ines JAK et STAT sont impliqu\u00e9es dans les m\u00e9canismes immunitaires qui conduisent \u00e0 l\u2019inflammation, et lorsqu\u2019elles sont d\u00e9r\u00e9gl\u00e9es, elles contribuent \u00e0 l\u2019auto-immunit\u00e9. Les inhibiteurs de JAK agissent en bloquant les signaux entre les prot\u00e9ines JAK et STAT, ce qui emp\u00eache le m\u00e9canisme auto-immune de fonctionner. Bien que le m\u00e9canisme JAK\/STAT ne soit pas le seul impliqu\u00e9 dans le m\u00e9canisme de l\u2019alop\u00e9cie areata, des \u00e9tudes ont montr\u00e9 que son inhibition peut entra\u00eener une croissance significative des cheveux chez de nombreuses patientes et de nombreux patients.<\/p>\n<p>Nous sommes tr\u00e8s heureux d\u2019apprendre l\u2019existence du projet THRIVE-AA2 et nous tiendrons la population canadienne au courant des derni\u00e8res nouvelles en mati\u00e8re de recherche d\u00e8s qu\u2019elles seront accessibles!<\/p>\n<p>Pour toute question concernant la recherche sur l\u2019alop\u00e9cie areata, n\u2019h\u00e9sitez pas \u00e0 contacter Anthony Gilding, directeur de la communication scientifique et de la recherche de la FCANAA \u00e0 <span style=\"color: #e31836;\"><a style=\"color: #e31836;\" href=\"mailto:science@canaaf.org\" target=\"_blank\" rel=\"noopener\">science@canaaf.org<\/a><\/span><\/p>\n<p>Pour toute autre question, veuillez contacter la FCANAA \u00e0 <span style=\"color: #e31836;\"><a style=\"color: #e31836;\" href=\"mailto:info@canaaf.org\" target=\"_blank\" rel=\"noopener\">info@canaaf.org<\/a> <span style=\"color: #000000;\">.<\/span><\/span><\/p>\n<p><span style=\"color: #e31836;\"><a style=\"color: #e31836;\" href=\"https:\/\/ir.concertpharma.com\/news-releases\/news-release-details\/concert-pharmaceuticals-initiates-thrive-aa2-phase-3-clinical\" target=\"_blank\" rel=\"noopener\">Voir le communiqu\u00e9 de presse complet ici<\/a>.<\/span><\/p>\n<\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_6 1_6 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:16.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:11.52%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:11.52%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":15270,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[358,355],"tags":[356],"class_list":["post-16025","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-essais-cliniques","category-recherche","tag-anthony-gilding-fr"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Concert Pharmaceuticals d\u00e9bute l&#039;essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543) - Fondation Canadienne de l\u2019Alop\u00e9cie Areata<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Concert Pharmaceuticals d\u00e9bute l&#039;essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543) - Fondation Canadienne de l\u2019Alop\u00e9cie Areata\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondation Canadienne de l\u2019Alop\u00e9cie Areata\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-27T19:19:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-04T15:11:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/05\/Science3.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"canaaf\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"canaaf\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/\"},\"author\":{\"name\":\"canaaf\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#\\\/schema\\\/person\\\/a056c978f094cc8f7b758a61444d18a1\"},\"headline\":\"Concert Pharmaceuticals d\u00e9bute l&rsquo;essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543)\",\"datePublished\":\"2021-05-27T19:19:25+00:00\",\"dateModified\":\"2022-08-04T15:11:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/\"},\"wordCount\":1628,\"image\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.canaaf.org\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Science3.jpeg\",\"keywords\":[\"Anthony Gilding\"],\"articleSection\":[\"Essais cliniques\",\"Recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/\",\"url\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/\",\"name\":\"Concert Pharmaceuticals d\u00e9bute l'essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543) - Fondation Canadienne de l\u2019Alop\u00e9cie Areata\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.canaaf.org\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Science3.jpeg\",\"datePublished\":\"2021-05-27T19:19:25+00:00\",\"dateModified\":\"2022-08-04T15:11:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#\\\/schema\\\/person\\\/a056c978f094cc8f7b758a61444d18a1\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.canaaf.org\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Science3.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.canaaf.org\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Science3.jpeg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Concert Pharmaceuticals d\u00e9bute l&rsquo;essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/\",\"name\":\"Fondation Canadienne de l\u2019Alop\u00e9cie Areata\",\"description\":\"Pr\u00e9visible pour une maladie impr\u00e9visible.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/#\\\/schema\\\/person\\\/a056c978f094cc8f7b758a61444d18a1\",\"name\":\"canaaf\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g\",\"caption\":\"canaaf\"},\"url\":\"https:\\\/\\\/www.canaaf.org\\\/fr\\\/author\\\/canaaf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Concert Pharmaceuticals d\u00e9bute l'essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543) - Fondation Canadienne de l\u2019Alop\u00e9cie Areata","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/","og_locale":"fr_FR","og_type":"article","og_title":"Concert Pharmaceuticals d\u00e9bute l'essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543) - Fondation Canadienne de l\u2019Alop\u00e9cie Areata","og_url":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/","og_site_name":"Fondation Canadienne de l\u2019Alop\u00e9cie Areata","article_published_time":"2021-05-27T19:19:25+00:00","article_modified_time":"2022-08-04T15:11:22+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/05\/Science3.jpeg","type":"image\/jpeg"}],"author":"canaaf","twitter_misc":{"\u00c9crit par":"canaaf","Dur\u00e9e de lecture estim\u00e9e":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/#article","isPartOf":{"@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/"},"author":{"name":"canaaf","@id":"https:\/\/www.canaaf.org\/fr\/#\/schema\/person\/a056c978f094cc8f7b758a61444d18a1"},"headline":"Concert Pharmaceuticals d\u00e9bute l&rsquo;essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543)","datePublished":"2021-05-27T19:19:25+00:00","dateModified":"2022-08-04T15:11:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/"},"wordCount":1628,"image":{"@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/#primaryimage"},"thumbnailUrl":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/05\/Science3.jpeg","keywords":["Anthony Gilding"],"articleSection":["Essais cliniques","Recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/","url":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/","name":"Concert Pharmaceuticals d\u00e9bute l'essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543) - Fondation Canadienne de l\u2019Alop\u00e9cie Areata","isPartOf":{"@id":"https:\/\/www.canaaf.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/#primaryimage"},"image":{"@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/#primaryimage"},"thumbnailUrl":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/05\/Science3.jpeg","datePublished":"2021-05-27T19:19:25+00:00","dateModified":"2022-08-04T15:11:22+00:00","author":{"@id":"https:\/\/www.canaaf.org\/fr\/#\/schema\/person\/a056c978f094cc8f7b758a61444d18a1"},"breadcrumb":{"@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/#primaryimage","url":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/05\/Science3.jpeg","contentUrl":"https:\/\/www.canaaf.org\/wp-content\/uploads\/2021\/05\/Science3.jpeg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.canaaf.org\/fr\/concert-pharmaceuticals-debute-lessai-clinique-de-phase-3-thrive-aa2-pour-les-inhibiteurs-de-jak-ctp-543\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.canaaf.org\/fr\/"},{"@type":"ListItem","position":2,"name":"Concert Pharmaceuticals d\u00e9bute l&rsquo;essai clinique de phase 3 THRIVE-AA2 pour les inhibiteurs de JAK (CTP-543)"}]},{"@type":"WebSite","@id":"https:\/\/www.canaaf.org\/fr\/#website","url":"https:\/\/www.canaaf.org\/fr\/","name":"Fondation Canadienne de l\u2019Alop\u00e9cie Areata","description":"Pr\u00e9visible pour une maladie impr\u00e9visible.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.canaaf.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.canaaf.org\/fr\/#\/schema\/person\/a056c978f094cc8f7b758a61444d18a1","name":"canaaf","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9e9992e9fe9731aca2131364fdeebff31804bf3f824bf344845475871356a949?s=96&d=mm&r=g","caption":"canaaf"},"url":"https:\/\/www.canaaf.org\/fr\/author\/canaaf\/"}]}},"_links":{"self":[{"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/posts\/16025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/comments?post=16025"}],"version-history":[{"count":2,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/posts\/16025\/revisions"}],"predecessor-version":[{"id":16027,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/posts\/16025\/revisions\/16027"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/media\/15270"}],"wp:attachment":[{"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/media?parent=16025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/categories?post=16025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.canaaf.org\/fr\/wp-json\/wp\/v2\/tags?post=16025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}